NCT05514509 - A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories | Biotech Hunter

Enrollment

162

Participants

Timeline

Start Date

October 28, 2022

Primary Completion Date

September 2, 2025

Study Completion Date

September 2, 2025

Conditions

HIV Infections

Interventions

DRUG

APRETUDE

Available as intramuscular injection.

DRUG

Cabotegravir tablet

Available as marketed orally administered tablets.

Trial Locations (22)

10001

GSK Investigational Site, Brooklyn

10029

GSK Investigational Site, New York

19114

GSK Investigational Site, Philadelphia

19147

GSK Investigational Site, Philadelphia

20005

GSK Investigational Site, Washington D.C.

20010

GSK Investigational Site, Washington D.C.

20017

GSK Investigational Site, Washington D.C.

23510

GSK Investigational Site, Norfolk

30303

GSK Investigational Site, Atlanta

30309

GSK Investigational Site, Atlanta

30312

GSK Investigational Site, Atlanta

32808

GSK Investigational Site, Orlando

33137

GSK Investigational Site, Miami

33401

GSK Investigational Site, West Palm Beach

33611

GSK Investigational Site, Tampa

38104

GSK Investigational Site, Memphis

48201

GSK Investigational Site, Detroit

75201

GSK Investigational Site, Dallas

77006

GSK Investigational Site, Houston

77021

GSK Investigational Site, Houston

89104

GSK Investigational Site, Las Vegas

06605

GSK Investigational Site, Bridgeport